Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061855 | 0.84 | MAPT (0.62) | MAPTTP53LMNAP2RX4TDP1 | |
| SCHEMBL8543010 | 0.83 | MAPT (0.58) | MAPTTP53LMNAPOLBKDM4E | |
| SCHEMBL1757848 | 0.83 | ACHE (0.59) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL29809414 | 0.83 | ACHE (0.59) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL31667662 | 0.83 | POLB (0.51) | MAPTTP53LMNAP2RX4POLB | |
| SCHEMBL31667461 | 0.82 | MAPK14 (0.56) | TP53KDM4EMEN1KMT2A | |
| SCHEMBL31006514 | 0.82 | ROCK2 (0.60) | MAPTTP53LMNAPOLBGRM2 | |
| SCHEMBL29283819 | 0.82 | ROCK2 (0.60) | MAPTTP53LMNAPOLBGRM2 | |
| SCHEMBL1412098 | 0.81 | LMNA (0.53) | MAPTTP53LMNAPOLBKDM4E | |
| SCHEMBL1571627 | 0.81 | MAPT (0.52) | MAPTTP53LMNAPOLBCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125745-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI SA (FR) | 2017-02-22 | — | — | EP | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2125745-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077551-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | MAPT 1428/4885TP53 2795/4885LMNA 1555/4885 |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | MYLK, MYLK2, MYLK3 | MAPT 1596/4885TP53 2765/4885LMNA 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.